Keros Therapeutics (KROS) EBIT Margin (2019 - 2025)
Keros Therapeutics (KROS) posted EBIT Margin of 15569.15% for Q4 2025, down 14193.98% on a QoQ basis from 108.92% in Q3 2025, and down 1381852.0% year-over-year from N/an in Q4 2024.
Keros Therapeutics (KROS) EBIT Margin (2019 - 2025) Analysis & Trends
Keros Therapeutics' EBIT Margin history runs 6 years deep, the most recent figure standing at 15569.15% for Q4 2025.
- Quarterly EBIT Margin fell 1381852.0% year-over-year to 15569.15% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 27.72% (up 602923.0% YoY) and the FY2025 annual result came in at 27.71%, up 596667.0% from the prior year.
- EBIT Margin was 15569.15% for Q4 2025 at Keros Therapeutics, down from 108.92% in the prior quarter.
- Across five years, EBIT Margin topped out at 71.97% in Q1 2025 and bottomed at 541000.0% in Q3 2023.
- A 5-year average of 56691.26% and a median of 8434.2% in 2024 frame the typical range for EBIT Margin.
- Annual changes were most pronounced in 2024 — EBIT Margin jumped 52588222 bps — and 2025, when it tumbled 1381852 bps.
- Keros Therapeutics' EBIT Margin stood at 27.18% in 2021, then slumped by 393 bps to 134.03% in 2022, then slumped by 24137 bps to 32486.01% in 2023, then surged by 95 bps to 1750.62% in 2024, then tumbled by 789 bps to 15569.15% in 2025.
- Business Quant data shows KROS's EBIT Margin at 15569.15% in Q4 2025, 108.92% in Q3 2025, and 219.16% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 30.35% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Keros Therapeutics | 374.82 Mn | 87.42 Mn | - | -15,569.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -15,569.15% |
| Sep 30, 2025 | -108.92% |
| Jun 30, 2025 | -219.16% |
| Mar 31, 2025 | 71.97% |
| Dec 31, 2024 | -1,750.62% |
| Sep 30, 2024 | -15,117.78% |
| Mar 31, 2024 | -58,413.25% |
| Dec 31, 2023 | -32,486.01% |
| Sep 30, 2023 | -541,000.00% |
| Mar 31, 2022 | -134.03% |
| Dec 31, 2021 | -27.18% |
| Jun 30, 2021 | -15,541.00% |
| Dec 31, 2019 | -109.12% |
| Sep 30, 2019 | -93.04% |
| Jun 30, 2019 | -106.04% |
| Mar 31, 2019 | -114.32% |